全球咳嗽过敏综合征市场 – 行业趋势和 2029 年预测

市场分析和规模                              

咳嗽反射是防止吸入的重要保护机制，但如果管理不善，可能会变得过敏。事实上，慢性咳嗽是一种严重的疾病，发病率很高。咳嗽过敏综合征现已被赋予了统一的范式。这是一种临床疾病，其主要症状是慢性咳嗽，与潜在疾病无关。虽然这仍然是一种理论，但新的研究表明，神经生理异常是这种疾病最常见的原因。近几十年来，我们对咳嗽机制的理解随着这种范式转变而不断发展，使我们能够在未来取得更大的进步。

Data Bridge Market Research 分析称，2021 年咳嗽过敏综合征市场价值为 83.1 亿美元，预计到 2029 年将达到 131.5 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 5.90%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Cough is the most common sickness worldwide, according to the WHO. The treatment algorithm is shifting away from small compounds and toward biologics and natural treatments. Combination therapy have become increasingly common in recent years. Clinical trials are underway for the majority of industry-sponsored products. Cough hypersensitivity syndrome has a severe impact on patients' lives, including sleep disruption, vomiting, light-headedness, and even rib fractures. Infections, gastroesophageal reflux disease (GERD), asthma, and other factors can all contribute to it. Companies in the cough hypersensitivity syndrome treatment market are boosting the availability of babapentin and pregabalin, which are GABA-related chemicals that operate as neuromodulators for the treatment of neuropathic pain and epilepsy, because chronic cough produces greater bodily discomfort. Gabapentin has been reported to be well tolerated in placebo-controlled trials for the treatment of refractory persistent cough.

Cough Hypersensitivity Syndrome Market Dynamics

Drivers

• Increasing prevalence of chronic respiratory diseases

The rising prevalence of chronic respiratory diseases is anticipated to drive the cough hypersensitivity syndrome market's growth. Cough is a prevalent illness that affects millions of individuals throughout the world. Globally, the prevalence of chronic respiratory disorders is increasing, resulting in an increase in chronic cough problems. As a result, the expanding disease burden provides a bright future for the global market. Although some research suggest that other factors, such as asthma, smoking, a hot and humid atmosphere, and viral or bacterial illness, may increase the likelihood of getting cough.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of cough hypersensitivity syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics. Healthcare industries are investing in opiates and GABA (gamma-aminobutyric acid)-related substances to help people with cough hypersensitivity. To treat chronic intractable cough, opiates are excellent cough suppressants and have antitussive actions. Similarly, corporations are expanding their tramadol production capabilities, an opioid prescription with a chemical makeup comparable to codeine medicines.

Furthermore, surging geriatric population and sedentary lifestyle of people such as high addiction of smoking will result in the expansion of cough hypersensitivity syndrome market. Along with this, favourable reimbursement policies and rising number of government initiatives to spread awareness will enhance the growth rate of the market.

Opportunities

• Rising number of clinical trials

Over the forecast period, the cough hypersensitivity syndrome market is expected to develop due to an increase in the number of clinical trials for the treatment of cough hypersensitivity syndrome. This is anticipated to boost the new market opportunities. The recent success of a P2X3 receptor antagonist in randomized clinical trials is the first major advancement in cough treatments in 30 years; it finally gives a method for treating persistent cough as well as a useful tool for unravelling the mechanism underlying cough hypersensitivity.

Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the cough hypersensitivity syndrome market growth.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the cough hypersensitivity syndrome market. Additionally, lack of awareness among people and inefficiency of drugs along with its adverse effects will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This cough hypersensitivity syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cough hypersensitivity syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cough hypersensitivity syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cough Hypersensitivity Syndrome Market

自 2019 年 12 月出现以来，COVID-19  病毒已传播到地球上几乎每个国家，促使世界卫生组织 (WHO) 宣布其为公共卫生紧急事件。COVID-19 是一种新型冠状病毒，被确定为肺炎病例的病原体。这种病毒迅速传播到世界各地，造成大量人员死亡。2020 年 3 月，世界卫生组织 (WHO) 将 COVID-19 列为全球大流行病，并建议采取严格措施防止该疾病传播。自那时以来，这场大流行推迟了医疗保健行业的扩张并扰乱了供应链。此外，许多国家的政府实施了全国封锁，以阻止 COVID-19 的传播。同样，世界各地许多国家的医疗保健组织都难以继续其供应链活动。咳嗽过敏综合征市场因供应链缓慢而受到阻碍。从好的方面来看，随着相关政府机构解除强制封锁限制，咳嗽过敏综合征市场可能会有所改善。由于各行业服务的应用范围广泛，预计新冠疫情过后各行业将迅速反弹。因此，预计未来市场将趋于稳定。

全球咳嗽过敏综合征市场范围

咳嗽过敏综合征市场根据药物类别、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

药物类别

• 吸入皮质类固醇
• 镇咳药
• 短效β-2激动剂
• 抗胆碱能药物
• 质子泵抑制剂
• 抗组胺药
• 其他的

给药途径

• 口服
• 吸入
• 其他的

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

咳嗽过敏综合征市场区域分析/见解

对咳嗽过敏综合征市场进行了分析，并按国家、药物类别、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

咳嗽过敏综合征市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在市场份额和市场收入方面占据咳嗽过敏综合征市场的主导地位，并将在预测期内继续保持主导地位。这是因为呼吸系统疾病的患病率很高，医疗支出的增加将进一步推动该地区市场的增长率。此外，主要关键参与者对新技术的日益关注将进一步推动该地区市场的增长率。

由于亚太地区人口数量激增，预计该地区在 2022-2029 年预测期内将实现增长。此外，医疗基础设施的发展和政府举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和咳嗽过敏综合征市场份额分析

咳嗽过敏综合征市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对咳嗽过敏综合征市场的关注有关。

咳嗽过敏综合征市场的一些主要参与者包括：

• Akorn 公司（美国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 勃林格殷格翰国际有限公司（德国）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 拜耳公司（德国）
• 默克公司（美国）
• Prestige Consumer Healthcare Inc.（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 百时美施贵宝公司 (美国)
• Almirall, SA（西班牙）
• Zenomed Healthcare Private Limited（印度）
• 卡迪拉制药（印度）

SKU-53276